Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Phase 3 data expected in the second half of 2024
Phase 3 data expected in the second half of 2024
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The collaboration brings a seamless digital experience to more formulators worldwide
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Lack of technology transfer stands out as a formidable barrier
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Subscribe To Our Newsletter & Stay Updated